Evaluation of the Clearview® Malaria pLDH as malaria rapid diagnostic test in travellers
© Houzé et al; licensee BioMed Central Ltd. 2010
Published: 20 October 2010
Malaria Rapid Diagnostic Tests (RDTs) are widely used to diagnose malaria. The present prospective study evaluated a new RDT, the Clearview® Malaria pLDH test targeting the pan-Plasmodium antigen lactate dehydrogenase (pLDH).
The Clearview® Malaria pLDH test was evaluated on fresh samples obtained in returned international travellers using microscopy corrected by PCR as the reference method. Included samples were P. falciparum (139), P. vivax (22), P. ovale (20), P. malariae (7), and 102 negative.
Overall sensitivity for the detection of Plasmodium sp. was 93.2%. For P. falciparum, the sensitivity was 98.6%; for P. vivax, P. ovale and P. malariae, overall sensitivities were 90.9%, 60.0% and 85.7% respectively. For P. falciparum and for P. vivax, the sensitivities increased to 100% at parasite densities above 100/μl. The specificity was 100%. The test was easy to perform and the result was stable for at least 1 hour.
The Clearview® Malaria pLDH was efficient for the diagnosis of malaria. The test was very sensitive for P. falciparum and P. vivax detection. The sensitivities for P. ovale and P. malariae were better than other RDTs .
- Maltha J, Gillet P, Bottieau E, Cnops L, van Esbroeck M, Jacobs J: Evaluation of a rapid diagnostic test (CareStrat TM Malaria HRP2/pLDH (Pf/pan) Combo Test) for the diagnosis of malaria in a reference setting. Malaria Journal. 2010, 9: 171-10.1186/1475-2875-9-171.PubMed CentralView ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.